Clinical Trial

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

Study acronym: Liver-NET1
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma. The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.
Protocol Amendment History 1 change
minor Completion pushed: 2027-03-15 -> 2029-03-19 2026-05-21
Trial Details
NCT Number NCT05546879
Lead Sponsor University Hospital, Grenoble
Collaborators: NETRIS Pharma
Conditions Hepatocellular Carcinoma
Enrollment 43 participants
Start Date 2023-03-15
Primary Completion 2026-03-19 (estimated)
Study Completion 2029-03-19 (estimated)
Updated on ClinicalTrials.gov 2026-05-20